Highly stabilized amorphous 3-bis(4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds.
3-Bis(4-Methoxyphenyl)methylene-2-indolinone (TAS-301) is a poorly water-soluble drug showing low oral bioavailability in rats and dogs. Previously, we reported that when a physical mixture of TAS-301 and a porous calcium silicate, Florite RE (FLR), was heated at high temperature (250 degrees C), the drug melted and was adsorbed by the FLR in an amorphous state, and that the preparation (melt-adsorbed product) showed a significantly increased solubility and dissolution rate, and a significantly enhanced oral bioavailability of the drug. The aim of the present study was to elucidate important factors for preparing a melt-adsorbed product showing greater stability of drug in an amorphous state. We examined the effects of the kind of adsorbent, drug/adsorbent ratio, heating conditions, and drug particle size on converting drug crystal into an amorphous state, the stability of amorphous state, and chemical stability of the drug in the melt-adsorbed products under a high temperature and high humidity condition (60 degrees C/80% RH, open). FLR, light anhydrous silicic acid and two types of hydrated silicon dioxides were tested as adsorbents. For the batch method, TAS-301 was converted into an amorphous state by heating TAS-301/adsorbents physical mixtures above the melting point of TAS-301 for more than 2 min. The amorphous state was most stabilized when FLR was used as an adsorbent and drug/FLR ratio was 1:0.5 and more. For the continuous method using the twin screw extruder that enables significantly larger scale manufacturing than batch method, TAS-301 melt-adsorbed products were able to produce when only FLR was used as adsorbent. The heating temperature was needed to be set above the melting point of TAS-301 to convert it into an amorphous state as well as batch method. The amorphous state was stabilized when drug/FLR ratio was 1:2 and more. The micronization of the drug decreased the stability of the amorphous state. These results indicate the importance of optimizing the above factors in the preparation of melt-adsorbed product.
Kinoshita
Masahiro
M
Pharmaceutical Research Laboratory, Taiho Pharmaceutical Co., Ltd., Hiraishi, Kawauchi-cho, Tokushima, Japan. m-kinoshita@taiho.co.jp
Baba
Kazuhiko
K
Nagayasu
Atsushi
A
Yamabe
Kanoo
K
Azuma
Mami
M
Houchi
Hitoshi
H
Minakuchi
Kazuo
K
D000327:Adsorption; D017610:Calcium Compounds / Q000737:chemistry*; D003460:Crystallization; D004339:Drug Compounding; D004355:Drug Stability; D006358:Hot Temperature; D007211:Indoles / Q000737:chemistry*; D010316:Particle Size; D017640:Silicates / Q000737:chemistry*; D012824:Silicic Acid / Q000737:chemistry; D012822:Silicon Dioxide / Q000737:chemistry; D012995:Solubility
D017610:Calcium Compounds; D007211:Indoles; D017640:Silicates; C112781:TAS 301; D012824:Silicic Acid; D012822:Silicon Dioxide; C031293:calcium silicate